SEC Comment Letter 0000000000-23-002081 to EQRx, Inc. (CIK 0001843762)

EQRx, Inc. (CIK 0001843762)
Date: March 1, 2023 · CIK: 0001843762 · Accession: 0000000000-23-002081

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269972

Date

March 1, 2023

Author

Division of Corporation Finance

Form

UPLOAD

Company

EQRx, Inc. (CIK 0001843762)

Letter

United States securities and exchange commission logo March 1, 2023 Melanie Nallicheri Chief Executive Officer EQRx, Inc. 50 Hampshire Street Cambridge, Massachusetts 02139

Re: EQRx, Inc. Registration Statement on Form S-3 Filed February 23, File No. 333-269972

Dear Melanie Nallicheri:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          March 1, 2023

       Melanie Nallicheri
       Chief Executive Officer
       EQRx, Inc.
       50 Hampshire Street
       Cambridge, Massachusetts 02139

                                                        Re: EQRx, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed February 23,
2023
                                                            File No. 333-269972

       Dear Melanie Nallicheri:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Alan
Campbell at 202-551-4224 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Marianne Sarrazin
</TEXT>
</DOCUMENT>

SecProbe.io